茲 提 述 瑋 俊 生 物 科 技 有 限 公 司（「本公司」）日 期 為 二 零 二 五 年 四 月 十 四 日、二 零 二 五 年 五 月 十 四 日、二 零 二 五 年 六 月 十 日、二 零 二 五 年 六 月 二 十 五 日 及 二 零 二 五 年 七 月 十 五 日 的 公 告，內 容 有 關 擬 議 根 據 特 別 授 權 發 行 新 可 換 股 債 券 的 關 連 交 易 以 及 延 遲 寄 發 通 函（「該等公告」）。除 另 有 所 指 外，本 公 告 所 用 詞 彙 與 該 等 公 告所界定者具有相同涵義。 誠 如 該 公 告 所 披 露，當 中 載 有（其 中 包 括）(i)認 購 事 項 以 及 擬 據 此 進 行 的 交 易（包 括 授 出 新 可 換 股 債 券 特 別 授 權）的 進 一 步 資 料；(ii)獨立董事委員會就認購協議向 獨立股東提供的推薦建議；(iii)獨立財務顧問函件；(iv)新可換股債券的詳情，連 同(v)股 東 特 別 大 會 通 告 的 通 函（「通 函」）預 計 將 於 二 零 二 五 年 七 月 三 十 一 日（星 期 四）或 之 前 寄 發 予 股 ...

Core Viewpoint - Fuyao is expected to achieve significant revenue growth and improved profitability in 2Q25, driven by various factors including better scale effects, reduced OEM rebate pressure, and cost savings from raw material and shipping cost deflation [1][2][3]. Revenue Growth - 2Q25 revenue is projected to grow by 13-14% YoY, reaching RMB10.7-10.8 billion, with domestic automotive glass revenue expected to rise over 15% YoY [2][3]. - Overseas auto glass sales are anticipated to see double-digit YoY growth, supported by increased production capacity at the US second-phase plant and steady export demand to Europe [2][3]. Profitability and Margins - Gross margin for 2Q25 is expected to expand by over 1 percentage point from 35.4% in 1Q25, aided by improved operational efficiencies and cost savings [1][2]. - The company is projected to achieve net income of RMB2.5-2.6 billion in 2Q25, marking another quarterly high, with FX gains estimated at over RMB300 million due to the Euro's appreciation against the RMB [1][3]. Overseas Operations - US manufacturing profitability is expected to improve, with the first-phase plant's capacity utilization and operational efficiency enhancing overall profitability [3]. - The second-phase plant is on track to narrow its losses compared to 2H24, with full-year operating margin expected to exceed the original target of 13% [3]. Strategic Positioning - Fuyao is leading among Chinese auto parts suppliers in expanding its global footprint, particularly in the US market, by leveraging local capacity and export supply [4]. - The company's flexible capacity allocation strategy amid tariff uncertainties enhances its operational resilience and risk resistance in a challenging geopolitical environment [4]. Valuation and Market Position - Fuyao's H-shares are currently trading at 16x 2025 P/E, which is considered undemanding, especially compared to peers like Nexteer and Minth [5]. - The anticipated solid operating performance in 2Q25 is expected to act as a catalyst for reversing the company's lagging stock price performance year-to-date [5].

董事会已审视及探求不同途径清偿股东贷款及其他贷款(连同应计利息)，并认为发行新可换股债券是降 低集团每年产生的利息开支金额、提升集团的财务状况及削减集团的资本负债比率的最有效及合适的方 法，原因在于新可换股债券每年2%的较低利率，将可尽量减轻集团的短期财政负担因三年总共能节省 利息约191.25万港元;集团的净流动负债也将改善，因认购事项生效后股东贷款及其他贷款(连同应计利 息)将从流动负债重新分类为非流动负债;公司赎回新可转换债券的财务压力减少因为新可转换债券到期 时赎回折扣为2%;股东贷款及其他贷款的本金额(连同应计利息)将于新可换股债券换股权获悉数行使后 全数清偿，毋须公司任何现金流出;及发行新可换股债券将不会对公司股权造成即时摊薄影响。 新可换股债券附带换股权，可按新可换股债券换股价每股新可换股债券换股股份0.07港元(可予调整)转 换为约2.14亿股新可换股债券换股股份。现有债券持有人一根据认购协议应付的认购款项将透过抵销公 司应付予现有债券持有人一及╱或其联系人的股东贷款及其他贷款(预期于完成日期将为1500万港元)项 下的未偿还本金额及应计利息而偿付。 玮俊生物科技(00660)公布，于2025 ...

Financial Performance - The company reported revenue of approximately HKD 161,056,000 for the six months ended December 31, 2024, a decrease of 15.4% compared to HKD 190,330,000 for the same period in 2023[8]. - Gross profit for the same period was approximately HKD 21,130,000, with a gross margin of 13.1%, compared to a gross profit of HKD 16,795,000 and a margin of 8.8% in the previous year, reflecting an increase of HKD 4,335,000 and 4.3% respectively[8]. - The company recorded a loss attributable to owners of approximately HKD 13,661,000, compared to a loss of HKD 6,734,000 in the same period last year, mainly due to impairment losses on receivables and increased depreciation and finance costs[9]. - The company incurred a loss before tax of HKD 11,202,000, compared to a loss of HKD 2,845,000 in the prior year, indicating a significant increase in losses[37]. - The net loss for the period was HKD 13,054,000, compared to a net loss of HKD 4,030,000 in the same period last year, reflecting a worsening financial performance[37]. - Basic and diluted loss per share was HKD 7.97, compared to HKD 3.93 in the previous year, indicating a higher loss per share[37]. - The company reported a net other comprehensive loss of HKD 510,000 for the period, compared to a gain of HKD 5,530,000 in the previous year[39]. - The company reported a loss attributable to shareholders of approximately HKD 13,661,000 for the six months ended December 31, 2024, compared to a loss of HKD 6,734,000 for the same period in 2023[67]. Expenses and Costs - Administrative expenses increased by 28.8% to approximately HKD 12,126,000, primarily due to increased depreciation of property, plant, and equipment in China[8]. - The company incurred a depreciation expense for property, plant, and equipment of HKD 6,585,000 for the six months ended December 31, 2024, compared to HKD 3,691,000 in the previous year[65]. - Employee costs, including director remuneration, amounted to approximately HKD 4,189,000 for the six months ending December 31, 2024, compared to HKD 3,591,000 for the same period in 2023[28]. - Interest expenses paid to the ultimate holding company amounted to HKD 139,000 for the six months ended December 31, 2024, compared to HKD 78,000 in the same period of 2023, reflecting an increase of 78.2%[75]. - The total salary for key management members increased to HKD 618,000 in the six months ended December 31, 2024, up from HKD 262,000 in the same period of 2023, representing a growth of 135.5%[77]. Debt and Liabilities - Total debt as of December 31, 2024, was approximately HKD 146,879,000, up from HKD 135,902,000 as of June 30, 2024[10]. - The net debt to total assets ratio was approximately 80.5% as of December 31, 2024, compared to 63.8% as of June 30, 2024[10]. - The company incurred a loss of HKD 13,661,000 during the reporting period, contributing to a total equity deficit of HKD (93,174,000) as of December 31, 2024[45]. - The company’s total liabilities exceeded total assets, resulting in a net asset deficiency of HKD (57,072,000) as of December 31, 2024[40]. Assets - As of December 31, 2024, non-current assets totaled HKD 87,468,000, down from HKD 95,100,000 as of June 30, 2024, representing a decrease of approximately 8.5%[40]. - Current assets decreased to HKD 92,870,000 from HKD 114,398,000, reflecting a decline of about 18.8%[40]. - The company’s trade receivables as of December 31, 2024, amounted to HKD 25,064,000, a decrease from HKD 34,945,000 as of June 30, 2024[69]. - The provision for impairment of trade receivables was HKD 1,953,000 as of December 31, 2024, compared to HKD 5,785,000 as of June 30, 2024[69]. - Cash and cash equivalents at the end of the period were HKD 1,784,000, down from HKD 2,161,000 at the beginning of the period[47]. Corporate Governance - The company is currently seeking suitable candidates to fill vacancies in the audit committee to comply with listing rules, following the resignation of a director[36]. - The audit committee is composed of two independent non-executive directors, which is below the required minimum of three members as per listing rules[36]. - The company has adopted corporate governance principles as per the listing rules, although it has not separated the roles of Chairman and CEO, which is a deviation from the guidelines[32]. - The company has adopted the Standard Code for Directors' Securities Transactions as per the Listing Rules Appendix C3, and all directors confirmed compliance during the six months ending December 31, 2024[31]. Strategic Plans and Market Position - The company aims to continue strategic acquisitions to capture new opportunities in the Chinese market and strengthen its revenue and profit base[13]. - The company is actively seeking growth projects for acquisition or investment and is in discussions with various parties regarding such opportunities[13]. - The board believes that the company will have sufficient cash resources to meet its operational funding and other financing needs for the next twelve months[53]. - The company is in discussions with potential investors to raise sufficient funds through financing arrangements[55]. Shareholder Information - The major shareholder, Mr. Lin Qingqu, holds 268,072,400 shares, representing approximately 156.33% of the issued shares[22]. - Onward Global Investments holds 12,863,500 shares, representing approximately 7.50% of the issued shares[22]. - Fair Concourse Limited holds 14,127,040 shares, representing approximately 8.24% of the issued shares[23]. - The company has not declared any interim dividends for the six months ended December 31, 2024[66]. Compliance and Reporting - The company has adopted all new and revised Hong Kong Financial Reporting Standards effective from July 1, 2023, with no significant impact on its financial performance or position expected[56]. - The company has no significant investments or capital asset plans as of December 31, 2024, apart from necessary capital expenditures for operations[17]. - There were no purchases, sales, or redemptions of any listed securities by the company or any of its subsidiaries during the six months ending December 31, 2024[30].

Financial Performance - For the six months ended December 31, 2024, the company reported revenue of HKD 161,056,000, a decrease of 15.4% compared to HKD 190,330,000 for the same period in 2023[2]. - The gross profit for the same period was HKD 21,130,000, representing a gross margin of 13.1%, compared to HKD 16,795,000 in 2023[2]. - The company incurred a loss before tax of HKD 11,202,000, compared to a loss of HKD 2,845,000 in the previous year, indicating a significant increase in losses[3]. - The net loss for the period was HKD 13,054,000, compared to HKD 4,030,000 in 2023, reflecting a year-over-year increase of 224.5%[3]. - Basic and diluted loss per share was HKD 7.97, compared to HKD 3.93 for the same period last year[3]. - The company reported a total comprehensive loss of HKD 13,564,000 for the period, compared to a comprehensive income of HKD 1,500,000 in the previous year[5]. - The group reported a loss attributable to the owners of the company of approximately HKD 13,661,000 for the six months ending December 31, 2024, compared to a loss of HKD 4,030,000 for the same period in 2023[12][22]. - The loss attributable to the company's owners increased to approximately HKD 13,661,000 for the six months ending December 31, 2024, compared to approximately HKD 6,734,000 for the six months ended December 31, 2023[39]. Assets and Liabilities - Non-current assets decreased to HKD 87,468,000 from HKD 95,100,000 as of June 30, 2024[7]. - Current assets also declined to HKD 92,870,000 from HKD 114,398,000, indicating a reduction in liquidity[7]. - Total liabilities amounted to HKD 237,410,000, down from HKD 253,847,000, showing a decrease in overall debt[8]. - The company's equity attributable to owners was a loss of HKD 93,174,000, compared to a loss of HKD 79,253,000 as of June 30, 2024[8]. - The net current liabilities of the group as of December 31, 2024, were approximately HKD 144,540,000, indicating significant uncertainty regarding the group's ability to continue as a going concern[12]. - Total debt as of December 31, 2024, was approximately HKD 146,879,000, up from approximately HKD 135,902,000 as of June 30, 2024[40]. - The net debt to total assets ratio increased to approximately 80.5% as of December 31, 2024, compared to approximately 63.8% as of June 30, 2024[40]. Revenue Sources - For the six months ending December 31, 2024, the revenue from the manufacturing and sales of modified starch and other biochemical products was approximately HKD 161,056,000, a decrease of 15.4% compared to HKD 190,330,000 for the same period in 2023[17][18]. - The group’s segment profit from modified starch and other biochemical products was HKD 4,522,000 for the six months ending December 31, 2024, down from HKD 7,959,000 for the same period in 2023[22]. - Segment profit from the manufacturing and sales of modified starch and biochemical products was approximately HKD 4,522,000 for the review period, down from approximately HKD 7,959,000 for the six months ended December 31, 2023[42]. Strategic Plans - The group plans to pursue strategic acquisitions to gain new opportunities in the Chinese market and strengthen its revenue and profit base[14]. - The group is actively seeking projects with growth potential for acquisition or investment and is in discussions with various parties regarding such opportunities[14]. - The company is actively seeking acquisition opportunities to gain new market opportunities in China and strengthen its revenue and profit base[42]. - The company is implementing measures to improve its financial situation, including discussions with potential investors to raise sufficient funds[42]. Expenses and Financial Management - Administrative expenses increased by 28.8% from approximately HKD 9,412,000 for the six months ended December 31, 2023, to approximately HKD 12,126,000 for the six months ending December 31, 2024[39]. - Sales expenses decreased by 27.7% from approximately HKD 6,938,000 for the six months ended December 31, 2023, to approximately HKD 5,432,000 for the six months ending December 31, 2024[39]. - The income tax expense for the six months ending December 31, 2024, was HKD 1,852,000, compared to HKD 1,185,000 for the same period in 2023[23]. Shareholder Information - The company did not recommend any interim dividend for the six months ended December 31, 2024, consistent with the previous period[27]. - The board has decided not to recommend an interim dividend for the six months ended December 31, 2024[44]. - The interim financial results for the six months ending December 31, 2024, will be published and sent to shareholders shortly[52]. Compliance and Governance - The audit committee currently consists of only two independent non-executive directors, which does not meet the minimum requirement of three members as per listing rules[51]. - The company is actively seeking suitable candidates to fill the vacancies in the audit committee to comply with listing rules by May 14, 2025[51]. Securities and Financing - The company has secured loans of approximately HKD 4,438,000 and has access to additional financing of approximately HKD 65,562,000 from its ultimate holding company to support its operations[12][16]. - The company has agreed to amend the terms of existing convertible bonds, including but not limited to the conversion price and maturity date[35]. - The company has not recognized any deferred tax liabilities due to the absence of taxable profits in Hong Kong for the periods under review[24]. - The company has not purchased, sold, or redeemed any of its listed securities during the six months ended December 31, 2024[45].

Financial Performance - The company reported revenue of approximately HKD 190,330,000 for the six months ended December 31, 2023, a decrease of 53.0% compared to HKD 405,080,000 for the same period in 2022[4]. - Gross profit for the same period was approximately HKD 16,795,000, with a gross margin of 8.8%, down from HKD 26,691,000 and a gross margin of 6.6% in the previous year, representing a decrease of 37.1%[4]. - The company recorded a loss attributable to owners of approximately HKD 6,734,000, an improvement from a loss of HKD 7,831,000 in the same period last year[5]. - Revenue from customers in China for the six months ended December 31, 2023, was approximately HKD 190,330,000, compared to HKD 387,331,000 for the same period in 2022, indicating a significant decrease[70]. - The total comprehensive loss for the six months ended December 31, 2023, was HKD 4,030,000, compared to a loss of HKD 5,308,000 for the same period in 2022, indicating an improvement of 24%[73][75]. Expenses and Costs - Administrative expenses decreased by 10.9% to approximately HKD 9,412,000 from HKD 10,566,000 in the prior period, primarily due to enhanced cost control measures[5]. - The total employee cost, including director remuneration, was approximately HKD 3,591,000, a decrease of 59.7% compared to HKD 8,920,000 for the same period in 2022[35]. - Central administrative expenses for the six months ended December 31, 2023, were HKD 2,101,000, down from HKD 3,501,000 in the same period of 2022, a reduction of 40%[73][75]. - The financial costs for the six months ended December 31, 2023, were HKD 8,829,000, compared to HKD 8,424,000 in the same period of 2022, showing an increase of 4.8%[73][75]. Assets and Liabilities - As of December 31, 2023, the company's current liabilities net value was approximately HKD 45,586,000, compared to HKD 29,657,000 as of June 30, 2023[6]. - The current ratio as of December 31, 2023, was approximately 0.79, slightly down from 0.81 as of June 30, 2023[6]. - The company's non-current assets increased to HKD 131,647 from HKD 111,059 as of June 30, 2023, reflecting a growth of 18.5%[53]. - The aging analysis of accounts payable shows a total of HKD 79,474,000 as of December 31, 2023, compared to HKD 63,945,000 as of June 30, 2023, indicating an increase in liabilities[87]. Strategic Plans and Investments - The company plans to continue strategic acquisitions to capture new opportunities in the Chinese market and strengthen its revenue and profit base[14]. - The company is actively seeking growth projects for acquisition or investment and is in discussions with multiple parties regarding these opportunities[14]. - The company has implemented measures to improve its financial situation, including financing from the ultimate holding company and ongoing discussions with potential investors[14]. - The group has no major investment or capital asset plans, aside from capital expenditures for operations, which will be funded by internal cash flow and borrowings[20]. Governance and Management - The company has adopted corporate governance practices in accordance with the listing rules, although it did not separate the roles of Chairman and CEO during the review period[40]. - The audit committee, consisting of two independent non-executive directors, reviewed the unaudited interim financial results for the six months ending December 31, 2023[47]. - The company is in the process of identifying suitable candidates to fill the vacancy left by the resignation of an independent non-executive director on August 9, 2023[41]. Shareholder Information - Major shareholders include Mr. Lin Qingqu, who holds 268,072,400 shares, representing approximately 156.33%[25]. - Onward Global Investments holds 12,863,500 shares, representing approximately 7.50%[25]. - Fair Concourse Limited holds 14,127,040 shares, representing approximately 8.24%[27]. Cash Flow and Financing - Cash generated from operating activities increased to HKD 24,665, compared to HKD 11,866 in 2022, marking a 107.5% increase[58]. - The company has secured loans of approximately HKD 4,641,000 and has access to additional financing of approximately HKD 65,359,000 from its ultimate holding company, Wei Jun Investment Fund[64]. - The board believes that the group will have sufficient cash resources to meet its operational funding and other financing needs for the next twelve months[65]. Employee and Director Remuneration - Total remuneration for directors and key management personnel for the six months ended December 31, 2023, was HKD 262,000, down from HKD 518,000 in the previous year[95]. - The group had a total of 130 employees as of December 31, 2023, up from 128 employees as of June 30, 2023[35].

Financial Performance - Revenue for the six months ended December 31, 2023, was HKD 190,330,000, a decrease of 53% compared to HKD 405,080,000 for the same period in 2022[2] - Gross profit for the same period was HKD 16,795,000, down 37% from HKD 26,691,000 year-on-year[2] - The net loss for the six months ended December 31, 2023, was HKD 4,030,000, an improvement from a net loss of HKD 5,308,000 in the previous year[3] - Basic and diluted loss per share was HKD 3.93, compared to HKD 4.57 for the same period in 2022[3] - The company reported a loss attributable to owners of approximately HKD 6,734,000 for the six months ended December 31, 2023, compared to a loss of HKD 7,831,000 for the same period in 2022, indicating a reduction in loss[37] - The company incurred a total comprehensive loss of HKD 4,030,000 for the six months ended December 31, 2023, compared to a loss of HKD 5,308,000 for the same period in 2022[22] Assets and Liabilities - Non-current assets increased to HKD 131,647,000 as of December 31, 2023, from HKD 111,059,000 as of June 30, 2023[7] - Current assets totaled HKD 133,902,000, slightly up from HKD 129,172,000 at the end of June 2023[7] - Current liabilities increased to HKD 179,488,000 from HKD 158,829,000, resulting in a negative net current liabilities of HKD 45,586,000[7] - As of December 31, 2023, the group's net current liabilities were approximately HKD 45,586,000, an increase from HKD 29,657,000 as of June 30, 2023[38] - The current ratio as of December 31, 2023, was approximately 0.79, slightly down from 0.81 as of June 30, 2023[38] - The asset-to-liability ratio (excluding cash and cash equivalents) was approximately 43.8% as of December 31, 2023, down from 53.3% as of June 30, 2023[38] Revenue Sources - Revenue from the manufacturing and sales of modified starch and other biochemical products was approximately HKD 190,330,000 for the six months ended December 31, 2023, a decrease of 53% compared to HKD 405,080,000 for the same period in 2022[17][22] - The company reported a segment profit of HKD 7,959,000 from modified starch and other biochemical products for the six months ended December 31, 2023, compared to HKD 8,067,000 for the same period in 2022[22] - The company continues to focus on the manufacturing and sales of modified starch and other biochemical products[11] Strategic Initiatives - The company plans to pursue strategic acquisitions to gain new opportunities in the Chinese market and strengthen its revenue and profit base[14] - The company is actively seeking growth projects for acquisition or investment and is in discussions with various parties regarding such opportunities[14] - The company has secured loans of approximately HKD 4,641,000 and has access to additional financing of about HKD 65,359,000 from its ultimate holding company, indicating efforts to ensure sufficient cash resources for operational needs[14][16] - The group continues to implement measures to improve its financial situation, including securing loans from the ultimate holding company and monitoring operational costs closely[39] Cost Management - Administrative expenses decreased by 10.9% to approximately HKD 9,412,000 for the six months ended December 31, 2023, down from HKD 10,566,000 in the same period of 2022[37] - The company’s cost control measures have contributed to a reduction in employee costs, impacting overall administrative expenses positively[37] - The company continues to implement measures to improve its working capital and cash flow, including close monitoring of general administrative expenses and operating costs[16] Taxation - The income tax expense for the six months ended December 31, 2023, was HKD 1,185,000, compared to HKD 1,529,000 for the same period in 2022[23] - The company has not incurred any tax liabilities in Hong Kong for the periods under review due to the absence of taxable profits[24] Dividends - The company did not recommend any interim dividend for the six months ended December 31, 2023, consistent with the previous year[27] - The company has decided not to declare an interim dividend for the six months ending December 31, 2023, consistent with the previous year[41] Compliance and Review - The board of directors has confirmed compliance with the standard code of conduct for securities transactions throughout the review period[44] - The audit committee has reviewed the unaudited interim financial results for the six months ending December 31, 2023[49]

Financial Performance - The company recorded revenue of approximately HKD 773.65 million for the year ended June 30, 2023, compared to HKD 1,007.19 million for the eighteen-month period ended June 30, 2022, representing a decline of about 23.2%[6] - Gross profit for the year was approximately HKD 50.41 million, with a gross margin of 6.52%, down from HKD 90.19 million and a gross margin of 8.95% in the previous period, indicating a decrease in profitability due to rising raw material costs[6] - The company reported a loss attributable to shareholders of approximately HKD 15.43 million for the year, compared to a loss of HKD 21.55 million in the previous period, reflecting an improvement despite the decline in gross profit[7] - The segment for modified starch and other biochemical products generated total revenue of approximately HKD 773.65 million, down from HKD 1,007.19 million in the previous period, with a segment profit of approximately HKD 18.07 million compared to HKD 49.28 million previously[8] Expenses and Liabilities - Administrative expenses decreased to approximately HKD 21.08 million from HKD 39.32 million in the previous period, primarily due to reduced employee costs as a result of stringent cost control measures[7] - As of June 30, 2023, the company's net current liabilities were approximately HKD 29.66 million, an increase from HKD 25.49 million a year earlier, with cash and cash equivalents of approximately HKD 6.31 million[10] - Total debt as of June 30, 2023, was approximately HKD 134.33 million, down from HKD 151.28 million, including borrowings of approximately HKD 59.29 million[11] - The company's asset-to-liability ratio (after deducting cash and cash equivalents) was approximately 53.0%, improved from 57.5% a year earlier[11] Corporate Governance - The board of directors has resolved not to recommend the payment of a final dividend for the year ended June 30, 2023, consistent with the previous year[15] - The company received annual independence confirmation from all independent non-executive directors, confirming their independence[35] - The company has adopted the corporate governance code as per the listing rules, ensuring compliance with relevant guidelines[88] - The board is responsible for overseeing the company's business management and approving development strategies and annual budgets[91] Shareholder Information - As of June 30, 2023, Lin Qing Qu holds 268,072,400 shares, representing approximately 156.33% of the issued share capital[47] - The company will issue 268,000,000 shares upon full exercise of the zero-coupon convertible bonds held by Lin Qing Qu[49] - Major shareholders, apart from the disclosed directors' interests, have notified the company of their relevant interests in the issued share capital as of June 30, 2023[51] - The company has not declared any distributable reserves for shareholders as of June 30, 2023, remaining unchanged from the previous year[31] Environmental, Social, and Governance (ESG) Initiatives - The group aims to integrate environmental, social, and governance (ESG) considerations into daily operations as a key component of corporate strategy[138] - The company emphasizes environmental protection and sustainable development in its operations[78] - The company has established clear guidelines for controlling emissions and waste disposal at its Shandong factory, with ongoing inspections by the environmental department and government agencies[153] - The company has implemented various environmental protection measures, including the installation of water meters, LED lights, and solar systems to reduce consumption[154] Employee Information - The total number of employees as of June 30, 2023, is 128, a decrease of 18% compared to the previous year[190] - Employee turnover rate for the group is 21%, a decrease of 3 percentage points from 24%[190] - The group provides medical benefits and health insurance to all full-time employees, ensuring a safe and healthy work environment[193] - Employee training is emphasized as a key component of human resource development to enhance skills and improve work quality[199] Risk Management - The company emphasizes the importance of internal control systems and risk management functions[92] - The board conducts annual corporate risk assessments to identify current and potential risks, including ESG factors[139] - The company has not established an internal audit department, opting for external independent professionals to review risk management and internal control systems[126] - The group is closely monitoring potential physical and transition risks related to climate change, including acute and chronic risks[186][187]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負 責，對其準確性及完整性亦不發表任何聲明，並明確表示概不就因本公告全部 或任何部分內容而產生或因依賴該等內容而引致之任何損失承擔任何責任。 瑋 俊 生 物 科 技 有 限 公 司 Wai Chun Bio-Technology Limited （於開曼群島註冊成立之有限公司） （股份代號：660） 截至二零二三年六月三十日止年度之年度業績 董事會謹此公佈本集團截至二零二三年六月三十日止年度（「本年度」）的經審核 綜合財務業績連同截至二零二二年六月三十日止十八個月期間的比較數字如下： 綜合損益表 截至二零二三年六月三十日止年度 截至 截至 二零二三年 二零二二年 六月三十日止 六月三十日止 年度 十八個月期間 附註 千港元 千港元 收入 5 773,654 1,007,186 銷售成本 (723,241) (917,001) 毛利 50,413 90,185 其他收入與其他收益及虧損之淨額 7 354 (6,475) 銷售費用 (14,792) (22,678) 行政費用 (21,082) (39,316) 應收款項（減值虧損）減值虧損撥回，淨 ...

Financial Performance - The company recorded revenue of approximately HKD 405,080,000 for the six months ended December 31, 2022, representing a 40.7% increase compared to HKD 287,873,000 for the same period in 2021[3]. - Gross profit for the same period was approximately HKD 26,691,000, with a gross margin of 6.6%, down from HKD 28,744,000 and 10.0% respectively in the previous year, indicating a decrease of HKD 2,053,000 and a drop of 3.4% in gross margin[3]. - The company reported a loss attributable to owners of approximately HKD 7,831,000 for the six months ended December 31, 2022, compared to a loss of HKD 4,474,000 in the same period of 2021, mainly due to impairment losses on trade receivables[4]. - The net loss for the six months ended December 31, 2022, was HKD 5,308,000, compared to a profit of HKD 1,791,000 in the same period of 2021[50]. - Total comprehensive loss for the period was HKD 8,210,000, compared to a comprehensive income of HKD 2,888,000 in the same period of 2021[50]. - Basic and diluted loss per share for the period was HKD 0.47, compared to HKD 0.27 in the previous year[49]. Cash Flow and Financial Position - The company’s cash and cash equivalents amounted to approximately HKD 17,747,000 as of December 31, 2022, compared to HKD 7,520,000 as of June 30, 2022[5]. - The net cash generated from operating activities for the six months ended December 31, 2022, was HKD 11,866,000, compared to a cash outflow of HKD 4,662,000 in the same period of the previous year[57]. - The company incurred cash outflows of HKD 2,159,000 for the purchase of property, plant, and equipment during the same period[57]. - The net cash inflow from financing activities was HKD 677,000 for the six months ended December 31, 2022, compared to HKD 263,000 in the previous year[57]. - The company has drawn loans of approximately HKD 1,536,000 and has secured additional financing of approximately HKD 68,464,000 from its ultimate holding company[63]. - The company reported a net asset deficit of HKD 2,173,000 as of December 31, 2022, compared to a net asset of HKD 6,037,000 as of June 30, 2022[53]. Operational Efficiency - Administrative expenses decreased by 24.3% to approximately HKD 10,566,000 from HKD 13,960,000 in the previous period, primarily due to enhanced cost control measures[4]. - The company’s operating cash flow and general administrative expenses will continue to be closely monitored to enhance operational efficiency[14]. - The company has implemented measures to improve its working capital and cash flow, including close monitoring of general administrative expenses and operating costs[66]. Shareholder Information - As of December 31, 2022, Mr. Lin Qingqu holds 1,368,004,000 shares, representing approximately 81.39% of the company[26]. - Onward Global Investments holds 128,635,000 shares, representing approximately 7.90% of the company[26]. - Fair Concourse Limited holds 141,270,400 shares, representing approximately 8.41% of the company[28]. Corporate Governance - The company has adopted the corporate governance code as per the listing rules, with a noted deviation regarding the separation of the roles of Chairman and CEO[42]. - The company has established an audit committee to oversee financial reporting and internal controls, consisting of three independent non-executive directors[46]. Future Plans and Strategic Initiatives - The company is actively seeking strategic acquisitions to capture new opportunities in the Chinese market and strengthen its revenue and profit base[14]. - The company plans to implement measures to improve its financial situation, including financing from the ultimate holding company and ongoing discussions with potential investors[14]. - The group plans to pursue strategic acquisitions to gain new opportunities in the Chinese market and strengthen its revenue and profit base[65]. Employee and Management Information - The total number of share options available for grant under the share option scheme as of December 31, 2022, is 69,963,946 shares[35]. - The total employee cost, including director remuneration, is approximately HKD 8,920,000, compared to HKD 8,046,000 for the same period last year[37]. - The total remuneration for directors and key management members for the six months ended December 31, 2022, was HKD 518,000, a decrease of 67.6% compared to HKD 1,598,000 for the same period in 2021[92]. - The company had a total of 142 employees as of December 31, 2022, down from 156 employees as of June 30, 2022[37]. Taxation and Compliance - The income tax expense for the six months ended December 31, 2022, was HKD 1,529,000, compared to HKD 1,072,000 for the same period in 2021[76]. - The company has not made any provisions for Hong Kong profits tax due to no taxable profits during the periods[77]. - The company has adopted all new and revised Hong Kong Financial Reporting Standards effective from July 1, 2022, with no significant impact on its financial performance and position expected[67].